Purpose: To retrospectively evaluate the safety of same-day discharge in patients who underwent liver microwave ablation compared with those admitted for overnight observation.
Purpose: Transarterial radioembolization (TARE) is commonly used for treatment of neuroendocrine tumor liver metastases (NETLMs). Hormonal release causing hemodynamic instability and carc...
Purpose: Colon cancer is the third most common cancer worldwide, and half of patients with colon cancer will develop liver metastasis. In the past decade, a number of locoregional approac...
Purpose: To conduct a meta-analysis to assess the safety and efficacy of yttrium-90 transarterial radioembolization (TARE) in treating breast cancer patients with hepatic metastasis
...
Purpose: Patients diagnosed with prostate cancer (PCa) are usually put into low and high risk groups. Patients in the low risk category often have a choice of undergoing Active Surveillan...
Purpose: The primary aims of TARGET were to determine relationships between tumor absorbed dose (TAD) or normal tissue absorbed dose (NTAD) and outcomes in hepatocellular carcinoma patien...
Purpose: Virtual biopsy is a non-invasive alternative for the surveillance and management of a variety of cancers. We describe the techniques of virtual biopsy and its applications in can...
Purpose: The aim of this study is to examine the clinical outcomes of yttrium-90 (Y90) transarterial radioembolization (TARE) of primary hepatocellular carcinoma (HCC) through evaluation ...
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
Transit Scientific Press Release
Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular
procedures, proudly announces the successful debut of XO...
Transit Scientific Press Release
Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular
procedures, proudly announces the successful debut of XO...
Siemens Healthineers and University Hospitals Cleveland News
Siemens Healthineers and University H...
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.
Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.
Embolization is a minimally invasive...
